AAIC 2025 Abstract·26 DecResults from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous AutoinjectorTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecSubcutaneous Lecanemab: Potential Benefits and Place in TherapyTrial in peopleInterventionsPaper
AAIC 2025 Abstract·25 DecClinical and Pharmacologic Profile of a Subcutaneous Lecanemab FormulationTrial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecThe Lecanemab Clarity AD Open‐Label Extension in Early Alzheimer’s Disease: Initial Findings From the 48‐Month AnalysisTrial in peopleInterventionsPaper